Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
Public ClinicalTrials.gov record NCT00704483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week, Open Label, Multicenter, Titration Study, With a 9-month Maintenance Treatment Extension, to Demonstrate Efficacy of SBR759 Compared to Sevelamer HCl in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis
Study identification
- NCT ID
- NCT00704483
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 321 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2008 (Type not available)
- Primary completion
- Aug 2010 (Actual)
- Completion
- Not listed
- Last update posted
- Dec 19, 2020
Started 2008
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis | Chula Vista | California | 91910 | — |
| Novartis | La Mesa | California | 91942 | — |
| Novartis | Whittier | California | 90602 | — |
| Novartis | Denver | Colorado | 80262 | — |
| Novartis | North Chicago | Illinois | 60064 | — |
| Novartis | Peoria | Illinois | 61602 | — |
| Novartis | Mishawaka | Indiana | 46545 | — |
| Novartis | Baltimore | Maryland | 21287 | — |
| Novartis | Fall River | Massachusetts | 02720 | — |
| Novartis | Springfield | Massachusetts | 01104 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68144 | — |
| Novartis | New York | New York | 10032 | — |
| Novartis | Winston-Salem | North Carolina | 27157-1082 | — |
| Novarits | Fargo | North Dakota | 58103 | — |
| Novartis | Portland | Oregon | 97210 | — |
| Novartis | Pittsburgh | Pennsylvania | 15224 | — |
| Novartis Investigative Site | Houston | Texas | 77024 | — |
| Novartis | San Antonio | Texas | 78207 | — |
| Novartis | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00704483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 19, 2020 · Synced Nov 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00704483 live on ClinicalTrials.gov.